Barclays PLC Edgewise Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 119,350 shares of EWTX stock, worth $3.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,350

Previous 119,350 -0.0%

Holding current value

$3.67 Million

Previous $3.19 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$15.88 - $29.5 $1.41 Million - $2.62 Million	88,826 Added 291.0%	119,350 $3.19 Million
Q2 2024 Aug 14, 2024	SELL	$15.08 - $21.23 $855,337 - $1.2 Million	-56,720 Reduced 65.01%	30,524 $549,000
Q1 2024 May 15, 2024	SELL	$9.25 - $19.97 $6.4 Million - $13.8 Million	-691,672 Reduced 88.8%	87,244 $1.59 Million
Q4 2023 Feb 15, 2024	BUY	$5.51 - $12.1 $4.19 Million - $9.2 Million	760,637 Added 4161.26%	778,916 $8.52 Million
Q3 2023 Nov 07, 2023	BUY	$5.73 - $7.69 $5,747 - $7,713	1,003 Added 5.81%	18,279 $105,000
Q2 2023 Aug 03, 2023	SELL	$5.71 - $10.29 $61,325 - $110,514	-10,740 Reduced 38.34%	17,276 $133,000
Q1 2023 May 04, 2023	BUY	$6.66 - $11.33 $65,154 - $110,841	9,783 Added 53.66%	28,016 $188,000
Q4 2022 Feb 13, 2023	BUY	$7.58 - $11.08 $67,598 - $98,811	8,918 Added 95.74%	18,233 $163,000
Q3 2022 Nov 03, 2022	SELL	$8.08 - $13.58 $1.7 Million - $2.85 Million	-209,993 Reduced 95.75%	9,315 $91,000
Q2 2022 Aug 12, 2022	SELL	$5.67 - $9.87 $3,696 - $6,435	-652 Reduced 0.3%	219,308 $1.75 Million
Q1 2022 May 16, 2022	BUY	$9.1 - $18.97 $2 Million - $4.17 Million	219,960 New	219,960 $2.13 Million

Others Institutions Holding EWTX

# of Institutions

191

Shares Held

100M

Call Options Held

2.17M

Put Options Held

410K

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account